Bright Minds Biosciences (DRUG) Total Liabilities (2020 - 2026)
Bright Minds Biosciences' (DRUG) quarterly Total Liabilities came in at $2.8 million in Q1 2026, up 451.76% YoY from $506527.3 in Q1 2025, and up 143.7% on a QoQ basis from $1.1 million in Q4 2025.
Bright Minds Biosciences (DRUG) Total Liabilities (2020 - 2026) Analysis & Trends
Bright Minds Biosciences (DRUG) has 7 years of Total Liabilities data on file, last reported at $2.8 million in Q1 2026.
- Quarterly Total Liabilities rose 451.76% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (up 451.76% YoY) and the FY2025 annual result came in at $1.7 million, up 314.57% from the prior year.
- Total Liabilities rose to $2.8 million in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $2.8 million in Q1 2026 to a low of $130602.2 in Q2 2024.
- A 5-year average of $770744.7 and a median of $547032.6 in 2023 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2023 — Total Liabilities slumped 82.31% — and 2026, when it soared 451.76%.
- Tracing DRUG's Total Liabilities over 5 years: stood at $429247.3 in 2022, then soared by 46.17% to $627410.9 in 2023, then tumbled by 34.78% to $409172.2 in 2024, then soared by 180.28% to $1.1 million in 2025, then surged by 143.7% to $2.8 million in 2026.
- The last three Total Liabilities figures came in at $2.8 million (Q1 2026), $1.1 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Bright Minds Biosciences | 733.05 Mn | 733.05 Mn | - | 2.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.79 Mn |
| Dec 31, 2025 | 1.15 Mn |
| Sep 30, 2025 | 1.73 Mn |
| Jun 30, 2025 | 481,983.42 |
| Mar 31, 2025 | 506,527.26 |
| Dec 31, 2024 | 409,172.21 |
| Sep 30, 2024 | 416,564.20 |
| Jun 30, 2024 | 130,602.17 |
| Mar 31, 2024 | 627,669.70 |
| Dec 31, 2023 | 627,410.87 |
| Sep 30, 2023 | 209,499.05 |
| Jun 30, 2023 | 547,032.60 |
| Mar 31, 2023 | 769,668.86 |
| Dec 31, 2022 | 429,247.34 |
| Sep 30, 2022 | 1.18 Mn |
| Jun 30, 2022 | 302,225.28 |
| Mar 31, 2022 | 792,250.41 |
| Dec 31, 2021 | 388,414.17 |
| Sep 30, 2021 | 507,288.34 |
| Jun 30, 2021 | 262,655.38 |